HIV and Hepatitis.com Coverage of
Digestive Disease Week 2007
May 19 - 24, 2007, Washington DC

Digestive Disease Week 2007 (DDW 2007) is considered the largest and most prestigious annual meeting in the United States for gastrointestinal (GI) professionals. Every year, this important conference attracts more than 16,000 physicians, researchers, and academics from around the world. In addition to GI issues, DDW also reports on the latest advances in hepatology, endoscopy, and cutting-edge technological advances. HIV and Hepatitis.com coverage of DDW 2007 will focus on the data presented at the Washington, DC, meeting on the treatment and management of chronic hepatitis C and hepatitis B, and HIV coinfection with these viruses.

Hepatitis C: FDA-approved Drugs

•Three Studies Assess Consensus Interferon for Hepatitis C in Prior Non-responders, Relapsers, and Patients with a High Likelihood of Treatment Failure
•A Follow-up Week 12 Viral Count Is Useful in Predicting SVR and Is 100% Accurate in Patients without Cirrhosis
•Treatment of Chronic Hepatitis C in Older Patients
•Asians with Genotype 1 HCV Respond as Well as Whites to Interferon-based Therapy
•Does Attainment of Sustained Virologic Response (SVR) from Treatment of HCV Constitute a Cure?
•Statins Improve Sustained Response to Interferon-based Therapy in Small Study
•Safety and Tolerability of Peginterferon Alfa-2a (Pegasys)/Ribavirin in HCV Patients Non-Tolerant or Nonresponsive to Peginterferon Alfa-2b (PegIntron)/Ribavirin
•Safety and Tolerability of Peginterferon Alfa-2a (Pegasys)/Ribavirin in HCV Patients Non-Tolerant or Nonresponsive to Peginterferon Alfa-2b (PegIntron)/Ribavirin
•Both Pegasys/Ribavirin and PegIntron/Ribavirin Combination Regimens Appear Similar in Efficacy and Safety in HCV Genotype 3 Patients
•Safety and Tolerability of Peginterferon Alfa-2a (Pegasys)/Ribavirin in HCV Patients Non-Tolerant or Nonresponsive to Peginterferon Alfa-2b (PegIntron)/Ribavirin
•Both Pegasys/Ribavirin and PegIntron/Ribavirin Combination Regimens Appear Similar in Efficacy and Safety in HCV Genotype 3 Patients
•Treatment with Pegasys Plus Ribavirin in Genotype 2/3 Chronic Hepatitis C Patients with Liver Cirrhosis
•Statins Improve Sustained Response to Interferon-based Therapy in Small Study

Hepatitis C: Experimental Drugs
•HCV-796 Plus PegIntron Shows Greater Antiviral Activity Across All HCV Genotypes Than Either Agent Used Alone
•Enhanced Clinical Effects and Favorable Resistance Profile with Combination of Boceprevir Plus HCV-796

Hepatitis B: FDA-approved Drugs
•Entecavir Produces Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in HBeAg-positive Patients
•Selected Telbivudine Studies Presented at DDW 2007
•Tenofovir Suppresses HBV in Patients Non-responsive to Adefovir, But Not in Those with Adefovir-resistant HBV
•Prognosis Following Hepatitis B Surface Antigen Clearance
•Liver Steatosis May Have No Impact on Treatment for Chronic Hepatitis B
•Entecavir Produces Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in HBeAg-positive Patients
•Hepatitis Delta Infection May Worsen Disease Progression in HIV-HBV Coinfected Individuals

Coinfection
•Adequate Doses of Ribavirin Are Critical for Achievement of Early Virological Response in HIV-HCV Coinfected Patients
•Alcohol Use Linked to Worse Liver Disease Progression in HIV-HCV Coinfected Patients
•Adequate Doses of Ribavirin Are Critical for Achievement of Early Virological Response in HIV-HCV Coinfected Patients
•Hepatitis Delta Infection May Worsen Disease Progression in HIV-HBV Coinfected Individuals


Digestive Disease Week 2007

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Digestive Disease Week 2007
DDW 2007 / DDW 2007 Coverage






Sponsors